# Phase 1A Safety Trial of Inhaled PK10571 (GB002)

> **NCT03473236** · PHASE1 · COMPLETED · sponsor: **GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Safety Issues

## Interventions

- **DRUG:** GB002
- **DEVICE:** Generic Dry Powder Inhaler
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03473236
- **Lead sponsor:** GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-06
- **Primary completion:** 2018-12-03
- **Final completion:** 2018-12-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473236, "Phase 1A Safety Trial of Inhaled PK10571 (GB002)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03473236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*